Jeffrey Eisele
CIK 1827326 · Chief Development Officer · last filed 2025-01-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
24
Lifetime Open-Market Net
-$1.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Development Officer | 55,312 | $41.03 | $2.27M | -$1.49M | 24 | 2025-01-30 |
Recent Filings · Page 2 of 3
24 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-02-27 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,646 | -$113.2K | EDGAR |
| 2023-02-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +9,061 | -$48.3K | EDGAR |
| 2023-01-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −883 | -$46.6K | EDGAR |
| 2023-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −367 | -$19.4K | EDGAR |
| 2023-01-25 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −4,479 | -$231.0K | EDGAR |
| 2023-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −2,033 | -$105.8K | EDGAR |
| 2023-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +22,580 | $0 | EDGAR |
| 2022-12-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −1,339 | -$4.6K | EDGAR |
| 2022-02-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −434 | -$16.7K | EDGAR |
| 2022-01-25 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +26,051 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.